Simcere Pharmaceutical's (HKG:2096) SANBEXIN has been included in the 2026 edition of the National Essential Medicines List.
The drug is used for the treatment of acute ischemic stroke, according to a Thursday Hong Kone bourse filing.
The company believes the inclusion is beneficial for the product to break through the limitations of class grade III type A (3A) hospitals, accelerate market penetration, and expand terminal prescription scenarios.